i2E

THG Energy Solutions, LLC specializes in providing energy management solutions through a comprehensive web-based platform. The company offers a range of services, including energy analytics, sustainability reporting, automated demand response, and load management, aimed at helping clients optimize their energy usage and reduce costs. With capabilities in data collection, verification, and accounts payable integration, THG serves a diverse clientele, including governments, healthcare facilities, educational institutions, multi-location retailers, and various commercial entities. Founded in 2003 and headquartered in Austin, Texas, with additional offices in Tulsa and Atlanta, THG Energy Solutions leverages its team's expertise in energy marketing, building controls, engineering, and data management to deliver tailored solutions that prioritize clients' interests. The company has formed a strategic alliance with Energy Hippo, Inc. to enhance its service offerings.

Simergent, LLC is a company that manufactures automated peritoneal dialysis devices aimed at providing affordable home dialysis solutions for both developed and emerging markets. Founded in 2014, the company is headquartered in Oklahoma City, Oklahoma, with additional operations in Chicago, Illinois. Simergent's devices are designed to be cost-effective and user-friendly, featuring a disposable tubing set that operates independently to troubleshoot issues. This innovation allows patients to maintain a normal lifestyle and socialize with family and friends while undergoing treatment at home.

BPEndo, LLC is a medical device company based in Norman, Oklahoma, founded in 2016. The company specializes in developing an insufflation retention device designed to address the problem of a deflating colon during colonoscopies. This innovative device creates an airtight seal in the rectum, which helps prevent air or fluid incontinence. By maintaining proper insufflation, the device allows physicians to maneuver the endoscope with greater freedom, ultimately enhancing the safety and efficiency of colonoscopic procedures.

Progentec Diagnostics, Inc. is focused on developing advanced diagnostic tests aimed at improving the management of systemic lupus erythematosus (SLE). The company's flagship platform, aiSLE DX, offers tools such as a flare prediction score, which proactively measures disease activity, and an early diagnosis test for lupus. Established in 2015 and headquartered in Oklahoma City, Oklahoma, Progentec collaborates with various research institutions and experts globally to leverage innovations in diagnostics. The company is dedicated to addressing significant unmet needs in healthcare by enhancing disease management through improved diagnostic capabilities, ultimately aiming to facilitate early detection and reduce disease incidence.

SendaRide, Inc. is a company based in Oklahoma City, Oklahoma, that specializes in providing non-emergency medical transportation services. Founded in 2016, SendaRide operates a platform tailored for the healthcare industry, enabling users to book both on-demand and pre-scheduled transportation. The application offers customized transport solutions for non-emergency medical patients, the elderly, and children, allowing users to find suitable transportation options easily. Additionally, the platform includes features such as GPS monitoring, live video feeds during transportation, and the ability to rate drivers or caretakers based on the services received. This comprehensive approach ensures that patients can reach their destinations safely and reliably.

Progentec Diagnostics, Inc. is focused on developing advanced diagnostic tests aimed at improving the management of systemic lupus erythematosus (SLE). The company's flagship platform, aiSLE DX, offers tools such as a flare prediction score, which proactively measures disease activity, and an early diagnosis test for lupus. Established in 2015 and headquartered in Oklahoma City, Oklahoma, Progentec collaborates with various research institutions and experts globally to leverage innovations in diagnostics. The company is dedicated to addressing significant unmet needs in healthcare by enhancing disease management through improved diagnostic capabilities, ultimately aiming to facilitate early detection and reduce disease incidence.

Moleculera Labs was founded by Drs. Craig Shimasaki and Madeleine Cunningham in 2011, to medically understand and clinically identify the underlying biological root of neurological, psychiatric, and behavioral disorders. Similar to the emergence of the immuno-oncology connection, epidemiological and research evidence demonstrates that a large portion of neuropsychiatric disorders are caused by an autoimmune dysfunction. The Company owns and operates a fully accredited clinical laboratory with its first revenue generating product—a blood panel called the Cunningham Panel™ that detects brain and nervous system targeted autoimmune antibodies in patients with neurologic, psychiatric, and behavioral disorders triggered by an infection. Patients are diagnosed with PANS, PANDAS, autism spectrum disorder, ADD/ADHD, bipolar disorder, anxiety disorder, Tourette’s, obsessive compulsive disorder (OCD), schizophrenia, or other neurologic and psychiatric syndromes, whereas the root may be a dysfunctional immune response. Symptoms include OCD, anxiety, depression, psychosis, motor or vocal tics, verbal and non-verbal communication difficulty, deteriorating social skills, eating disorders, academic regression, and rage. These patients are typically prescribed neuropsychiatric drugs, often resulting in little or no improvement. However, once a patient is correctly diagnosed through testing, treatment is redirected towards the immune system, neuroinflammation, and subclinical infections, resulting in remarkable recoveries, sometimes after decades of suffering. Moleculera is the sole clinical laboratory performing this panel covered by two U.S. patents. The Company has received and processed over 13,000 blood specimens ordered by over 1,700 physicians in over 50 countries, all prior to launching a sales force. The Company generated $1.1 MM in 2021 and is preparing to scale for revenue expansion with expectations of revenue ~$25 MM in 4-5 years. The company is now applying this technology to autoimmune cardiovascular disease and Long-COVID symptoms. The basic research that led to the identification of these antineuronal antibody targets was studied for over 20 years in the laboratory of Dr. Madeleine Cunningham at The University of Oklahoma Health Sciences Center, with subsequent collaboration from the Pediatric Branch of the National Institutes of Mental Health (NIMH). Scientific and clinical results have been published in multiple top-tier peer-reviewed journals. Certain infections that have been found to trigger these autoimmune antibodies include strep, Lyme, mycoplasma, Babesia, bartonella, coxsackie virus, and others. Medical journals have reported an autoimmune response to SARS-CoV-2 (COVID-19), with approximately one-third of patients experiencing some neurologic or psychiatric symptoms. The patented Cunningham Panel™ consists of five tests. Four which measure levels of autoantibodies directed against Dopamine D1 receptor, Dopamine D2L receptor, Lysoganglioside GM1, and Tubulin. A fifth test measures CaM Kinase II activation, a key enzyme involved in the production of neurotransmitters dopamine, epinephrine, and norepinephrine. Autoimmune antibodies that bind to these targets interfere with or block normal neurologic activity in the brain and nervous system. The laboratory results assist a physician in making a diagnosis and identifying the appropriate therapy. In addition to individual clinicians who order the panel, the Company has provided testing to over 80 medical institution customers. In a 2020 publication in the Journal of Neuroimmunology, the Cunningham Panel demonstrated an 88% sensitivity and 92% specificity with an accuracy of 90% correlating these autoantibody elevations and neuropsychiatric symptoms before and after treatment. The Cunningham Panel aids a clinician’s treatment decision by directing them to the underlying subclinical infections and neuroimmune dysfunction, rather than simply treating symptoms. Effective treatments typically include various anti-infectives, anti-inflammatory agents and immunomodulators. Moleculera' s Test Panel generates an average realized revenue of $900 through existing CPT codes and patient billing. The Company has generated over $10 million in cumulative revenue since opening. During the COVID-19 pandemic, revenues for 2021 were $1.1 million, all prior to adding a sales force. Approximately 10% of orders come from a growing international market, with the Company receiving orders from over 1,700 clinicians. Moleculera Labs has one of the largest IRB approved and clinically annotated serum specimen biobanks of over 13,000 specimens utilized for research and development of new products for autoimmune neuropsychiatric disorders. The Company has demonstrated its panel’s clinical utility in multiple neuropsychiatric disorders and have been able to predict treatment efficacy while working with pharmaceutical and research partners to assist in identifying novel drug targets. There is a clear unmet medical need and demand in this $23 billion dollar neuropsychiatric and behavioral disorder market. Moleculera recently in-licensed exclusive technology for multiple autoimmune antibody targets against the heart, which are implicated in a portion of multiple cardiovascular diseases such as heart failure, cardiomyopathy, atrial fibrillation, and myocarditis. With this technology along with proposed clinical studies and validation in process, the Company expects to develop and commercialize two additional panels. One panel will target various cardiovascular diseases (world-wide market of $4.9 trillion) infection-triggered autoimmunity, and another panel for diagnosing and treatment-monitoring of Long-COVID (estimated at $6.5 trillion). Our precision medicine business model is fashioned after Foundation Medicine and Genomic Health, whose precision medicine companies were acquired by Roche in 2018 for $5.3 billion, and Exact Sciences in 2019 for $2.8 billion, respectively. Moleculera Labs is led by Dr. Craig Shimasaki, a serial entrepreneur with over 35 years of biotechnology experience, who began his career at Genentech. He co-founded multiple companies, participated in taking several companies public into the U.S. and the Canadian stock exchange, led five products through the FDA diagnostic approval process, and has directed two CLIA labs, raising over $30 million for these companies. Dr. Madeleine Cunningham, Chief Scientific Officer, is an internationally recognized leader in infection-induced autoimmune neuropsychiatric disorders and is a tenured professor at the University of Oklahoma with over 40 years of research and over 130 authored publications in leading scientific and medical journals. Dr. James Appleman is VP of R&D and Clinical Development and has 30+ years’ experience in building successful diagnostic and therapeutic companies from inception through successful exits, including a $230M exit to Roche. Mr. Fred Hiller is CFO and brings 45+ years’ experience in corporate finance and accounting. He began his career at Touche Ross & Co. in 1962, serving as controller at Elgin National and Columbia Pictures, and CFO at Wilkinson Sword. He has been a financial consultant to numerous companies including two biotechnology companies and one that was publicly traded.

Synereca Pharmaceuticals, Inc. is a research-stage biopharmaceutical company focused on developing orally active drugs that enhance the effectiveness of existing antibiotics. Founded in 2009 and headquartered in Chapel Hill, North Carolina, with additional laboratories in Oklahoma City, the company specializes in compounds that improve the activity of Colistin against gram-negative bacteria while minimizing toxicity. Its portfolio includes prototypic RecA inhibitors targeting various pathogenic bacteria, such as E. coli, which are responsible for critical infections, including those of the lungs, urinary tract, and skin. Synereca's platform identifies multiple chemical subclasses of compounds designed to potentiate current classes of antibiotics, including polymyxins, carbapenems, aminoglycosides, and fluoroquinolones, thereby providing drug manufacturers with effective solutions for bacterial infections.

Well Checked Systems International, LLC, operating as WellChecked, specializes in remote monitoring solutions for oil and gas well sites. Founded in 2012 and based in Tulsa, Oklahoma, the company provides a comprehensive platform that includes video monitoring, reporting, alerting, and data storage. Its services are designed to assist pumpers, owners, and operators by enabling them to monitor well site activity from a distance. Key features include motion sensing, gate activity monitoring, tank level change alerts, and cloud-based video surveillance for easy retrieval. The platform aims to enhance safety and security while minimizing the costs and personnel required for on-site monitoring, thereby helping to prevent equipment damage and loss.

Otologic Pharmaceutics, Inc. is a biopharmaceutical company focused on developing innovative treatments for hearing disorders. Established in 2009 and located in Oklahoma City, the company is dedicated to addressing acute hearing loss, particularly through its lead product, HPN1010, an oral medication designed to treat acute noise-induced hearing loss. Otologic aims to prevent the progression to permanent hearing impairment and has plans to extend the applications of HPN1010 to other forms of hearing loss, including those caused by chemotherapy drugs like Cisplatin. Additionally, the company's research encompasses a range of therapeutic approaches, including programs for cochlear implant-related hearing loss and conditions such as Meniere's disease and tinnitus. By advancing these novel pharmacological solutions, Otologic Pharmaceutics seeks to improve the quality of life for individuals suffering from hearing impairment.

Moleculera Labs was founded by Drs. Craig Shimasaki and Madeleine Cunningham in 2011, to medically understand and clinically identify the underlying biological root of neurological, psychiatric, and behavioral disorders. Similar to the emergence of the immuno-oncology connection, epidemiological and research evidence demonstrates that a large portion of neuropsychiatric disorders are caused by an autoimmune dysfunction. The Company owns and operates a fully accredited clinical laboratory with its first revenue generating product—a blood panel called the Cunningham Panel™ that detects brain and nervous system targeted autoimmune antibodies in patients with neurologic, psychiatric, and behavioral disorders triggered by an infection. Patients are diagnosed with PANS, PANDAS, autism spectrum disorder, ADD/ADHD, bipolar disorder, anxiety disorder, Tourette’s, obsessive compulsive disorder (OCD), schizophrenia, or other neurologic and psychiatric syndromes, whereas the root may be a dysfunctional immune response. Symptoms include OCD, anxiety, depression, psychosis, motor or vocal tics, verbal and non-verbal communication difficulty, deteriorating social skills, eating disorders, academic regression, and rage. These patients are typically prescribed neuropsychiatric drugs, often resulting in little or no improvement. However, once a patient is correctly diagnosed through testing, treatment is redirected towards the immune system, neuroinflammation, and subclinical infections, resulting in remarkable recoveries, sometimes after decades of suffering. Moleculera is the sole clinical laboratory performing this panel covered by two U.S. patents. The Company has received and processed over 13,000 blood specimens ordered by over 1,700 physicians in over 50 countries, all prior to launching a sales force. The Company generated $1.1 MM in 2021 and is preparing to scale for revenue expansion with expectations of revenue ~$25 MM in 4-5 years. The company is now applying this technology to autoimmune cardiovascular disease and Long-COVID symptoms. The basic research that led to the identification of these antineuronal antibody targets was studied for over 20 years in the laboratory of Dr. Madeleine Cunningham at The University of Oklahoma Health Sciences Center, with subsequent collaboration from the Pediatric Branch of the National Institutes of Mental Health (NIMH). Scientific and clinical results have been published in multiple top-tier peer-reviewed journals. Certain infections that have been found to trigger these autoimmune antibodies include strep, Lyme, mycoplasma, Babesia, bartonella, coxsackie virus, and others. Medical journals have reported an autoimmune response to SARS-CoV-2 (COVID-19), with approximately one-third of patients experiencing some neurologic or psychiatric symptoms. The patented Cunningham Panel™ consists of five tests. Four which measure levels of autoantibodies directed against Dopamine D1 receptor, Dopamine D2L receptor, Lysoganglioside GM1, and Tubulin. A fifth test measures CaM Kinase II activation, a key enzyme involved in the production of neurotransmitters dopamine, epinephrine, and norepinephrine. Autoimmune antibodies that bind to these targets interfere with or block normal neurologic activity in the brain and nervous system. The laboratory results assist a physician in making a diagnosis and identifying the appropriate therapy. In addition to individual clinicians who order the panel, the Company has provided testing to over 80 medical institution customers. In a 2020 publication in the Journal of Neuroimmunology, the Cunningham Panel demonstrated an 88% sensitivity and 92% specificity with an accuracy of 90% correlating these autoantibody elevations and neuropsychiatric symptoms before and after treatment. The Cunningham Panel aids a clinician’s treatment decision by directing them to the underlying subclinical infections and neuroimmune dysfunction, rather than simply treating symptoms. Effective treatments typically include various anti-infectives, anti-inflammatory agents and immunomodulators. Moleculera' s Test Panel generates an average realized revenue of $900 through existing CPT codes and patient billing. The Company has generated over $10 million in cumulative revenue since opening. During the COVID-19 pandemic, revenues for 2021 were $1.1 million, all prior to adding a sales force. Approximately 10% of orders come from a growing international market, with the Company receiving orders from over 1,700 clinicians. Moleculera Labs has one of the largest IRB approved and clinically annotated serum specimen biobanks of over 13,000 specimens utilized for research and development of new products for autoimmune neuropsychiatric disorders. The Company has demonstrated its panel’s clinical utility in multiple neuropsychiatric disorders and have been able to predict treatment efficacy while working with pharmaceutical and research partners to assist in identifying novel drug targets. There is a clear unmet medical need and demand in this $23 billion dollar neuropsychiatric and behavioral disorder market. Moleculera recently in-licensed exclusive technology for multiple autoimmune antibody targets against the heart, which are implicated in a portion of multiple cardiovascular diseases such as heart failure, cardiomyopathy, atrial fibrillation, and myocarditis. With this technology along with proposed clinical studies and validation in process, the Company expects to develop and commercialize two additional panels. One panel will target various cardiovascular diseases (world-wide market of $4.9 trillion) infection-triggered autoimmunity, and another panel for diagnosing and treatment-monitoring of Long-COVID (estimated at $6.5 trillion). Our precision medicine business model is fashioned after Foundation Medicine and Genomic Health, whose precision medicine companies were acquired by Roche in 2018 for $5.3 billion, and Exact Sciences in 2019 for $2.8 billion, respectively. Moleculera Labs is led by Dr. Craig Shimasaki, a serial entrepreneur with over 35 years of biotechnology experience, who began his career at Genentech. He co-founded multiple companies, participated in taking several companies public into the U.S. and the Canadian stock exchange, led five products through the FDA diagnostic approval process, and has directed two CLIA labs, raising over $30 million for these companies. Dr. Madeleine Cunningham, Chief Scientific Officer, is an internationally recognized leader in infection-induced autoimmune neuropsychiatric disorders and is a tenured professor at the University of Oklahoma with over 40 years of research and over 130 authored publications in leading scientific and medical journals. Dr. James Appleman is VP of R&D and Clinical Development and has 30+ years’ experience in building successful diagnostic and therapeutic companies from inception through successful exits, including a $230M exit to Roche. Mr. Fred Hiller is CFO and brings 45+ years’ experience in corporate finance and accounting. He began his career at Touche Ross & Co. in 1962, serving as controller at Elgin National and Columbia Pictures, and CFO at Wilkinson Sword. He has been a financial consultant to numerous companies including two biotechnology companies and one that was publicly traded.

Synercon Technologies, LLC specializes in developing advanced technology solutions for extracting crash data from the engine control modules of heavy vehicles, including trucks and buses. The company offers a range of products, such as the Forensic Link Adapter (FLA), which downloads data from heavy vehicles, and the Smart Sensor Simulator, which allows investigators to emulate vehicle functions for bench downloads without generating extraneous fault codes. Additionally, Synercon provides TruckCRYPT, a software solution that encrypts and presents the data extracted from the FLA. Beyond its hardware and software offerings, the company delivers services in chip-level digital forensics, heavy vehicle data extraction, crash reconstruction, expert testimony, electronics design, embedded Linux implementations, and vehicle networking. Founded in 2013 and headquartered in Tulsa, Oklahoma, Synercon Technologies aims to enhance forensic investigations by ensuring the integrity of vital vehicle data post-accident.

Drik is an Oklahoma City-based provider of toxicology services for companies developing new drugs. Led by Kumar Sripathirathan, founder and CEO, Drik provides customized testing which help researchers and pharmaceutical companies identify toxicology requirements and the safety of new drugs under development.

Medefy is a healthcare app founded in 2018 and based in Tulsa, Oklahoma, that facilitates direct communication between employers and their employees regarding health benefits. The platform empowers health plan members by providing personalized guidance throughout their healthcare journey, helping them navigate the complexities of benefits offerings. Medefy enables employees to shop for better-priced, higher-quality healthcare providers in their area, while also offering tools such as telemedicine, narrow networks, and chronic disease management. By fostering engagement and informed decision-making, Medefy aims to improve healthcare outcomes and enhance the overall benefits experience for both employers and employees.

Docvia is a privately held software venture that provides secure, HIPAA-compliant electronic access between established patients and their health providers. The company's software was first commercially deployed at St. John Health System in Tulsa, Oklahoma. The Docvia team is comprised of practicing physicians, software engineers and designers that work together with community leaders in order to provide safe, simple and inexpensive health access around the world.

Expert TA, LLC offers a web-based grading software solution designed for professors and teaching assistants to efficiently grade homework assignments in subjects such as engineering, mathematics, physics, and chemistry. Founded in 2009 and based in Tulsa, Oklahoma, the company provides features like Homework Mode, which allows educators to create assignments and export grade information for integration with other software, and Tutorial Mode, which simulates the guidance a student might receive during tutoring sessions. This technology enables educators to focus more on teaching while the software handles the complex partial-credit grading of homework problems, enhancing both student learning and teaching effectiveness.

Exerbotics, LLC specializes in manufacturing advanced fitness and wellness equipment designed to enhance healthy living and improve quality of life. Established in 2004 and based in Tulsa, Oklahoma, the company provides a range of products for medical rehabilitation, senior living, and research applications. Their equipment includes machines for various muscle groups, such as chest press, shoulder press, squat, and leg extensions, which measure and record force output for analysis and training purposes. Exerbotics' technology not only tracks capability and monitors activity but also delivers detailed reports on biometrics and workout performance, ensuring that users can compare actual work against prescribed regimens.

Lifetone Technology develops and markets lifesaving alarming devices. It offers bedside fire alarms and clocks that protect against residential fires; and a bed shaker, which produces strong and intermittent vibration. The company sells its products online, as well as through dealers to children, heavy sleepers, seniors, and people with hearing loss in the United States. Lifetone Technology was formerly known as InnovAlarm Corporation and changed its name to Lifetone Technology in 2008. The company was founded in 2004 and is based in Oklahoma City, Oklahoma with additional offices in Chicago.